Medical & affiliate disclosure: CTX Stat provides educational laboratory information and is not a substitute for professional medical advice, diagnosis, or treatment. CTX Stat may receive compensation from some outbound provider links when an affiliate program is active; provider comparisons and rankings are based on consumer fit, effective cost, access, policies, and reputation—not commission.
Quick take: what BRCA testing usually costs
BRCA testing cost depends less on the genes themselves and more on how the test is ordered. A comprehensive clinical hereditary cancer test that includes BRCA1 and BRCA2 is often available through self-pay programs for about $249–$299 before any shipping, clinician, collection, or visit fees. Insurance-billed testing can cost little or nothing for people who meet medical criteria, but it can also expose you to deductible or coinsurance costs if benefits are unclear.
For most consumers, the key question is not “Which BRCA test is cheapest?” It is: What is the effective total cost for a clinically appropriate test that your doctor or genetic counselor can use? That total includes the test, any required telehealth order, sample collection, shipping, counseling, and possible follow-up testing for relatives.
What BRCA testing checks
BRCA1 and BRCA2 are tumor-suppressor genes. Some inherited harmful changes in these genes can raise the risk of breast, ovarian, pancreatic, prostate, and certain other cancers. The National Cancer Institute explains that inherited harmful BRCA changes are associated with higher cancer risk, but a genetic test does not diagnose cancer and does not predict with certainty whether cancer will occur. NCI’s BRCA fact sheet is a useful patient-friendly reference.
When people say “BRCA test,” they may mean different things:
- Comprehensive BRCA1/BRCA2 testing: sequencing plus deletion/duplication analysis of the two BRCA genes.
- Hereditary breast and ovarian cancer panel: BRCA1/2 plus other genes such as PALB2, ATM, CHEK2, TP53, PTEN, CDH1, RAD51C, and RAD51D, depending on the lab.
- Broad hereditary cancer panel: BRCA1/2 plus genes linked to colorectal, uterine, pancreatic, melanoma, gastric, endocrine, or other hereditary cancer syndromes.
- Selected-variant consumer screening: a limited direct-to-consumer report that looks for specific BRCA variants, not all clinically relevant BRCA variants.
- Known family variant testing: targeted testing for the exact variant already found in a biological relative.
This distinction matters because a low-cost consumer DNA report may not answer the same medical question as a clinical hereditary cancer panel. The NCI notes that the FDA-authorized direct-to-consumer inherited cancer risk test historically covered only selected BRCA variants, and the CDC cautions that direct-to-consumer BRCA testing is not a substitute for comprehensive clinical testing when personal or family history suggests risk. See the CDC’s guidance on taking a genetic test on your own.
BRCA testing cost by ordering route
The same genetic question can produce very different bills depending on the route. Use the table below to compare effective cost to the patient, not just the advertised test price.
| Ordering route | Typical effective cost | What is usually included | Best fit | Cost cautions |
|---|---|---|---|---|
| Self-pay clinical hereditary cancer test | Often about $249–$299 before shipping or optional add-ons | Clinical lab test, saliva or blood sample, report; may include or offer genetic counseling | People who want predictable cash pricing or do not meet insurance criteria | Confirm whether clinician review, shipping, and counseling are included or separate. |
| Provider-ordered insurance billing | $0 to deductible/coinsurance exposure, depending on plan | Test ordered by clinician or genetics clinic; may include preauthorization and counseling | People who meet medical criteria, have cancer treatment implications, or want testing integrated into care | Ask for prior authorization, in-network status, and a written out-of-pocket estimate. |
| Hospital or cancer-center genetics clinic | Visit copay plus test cost; sometimes $0 when covered, sometimes much higher if denied | Detailed risk assessment, counseling, test selection, medical-record integration | Complex family history, current cancer diagnosis, prior uncertain result, or need for treatment planning | Facility and professional fees may be separate from the lab test. |
| Direct-to-consumer selected BRCA variant report | Often lower upfront consumer-kit pricing | Consumer DNA kit and selected BRCA variant report | General awareness only, especially when no strong risk history is present | Not comprehensive; negative result can be falsely reassuring if used as a clinical rule-out. |
| Known family variant testing | Often less expensive than full panel; varies by lab and relationship program | Targeted test for the familial pathogenic variant | Biological relatives of someone with a documented pathogenic or likely pathogenic variant | You usually need a copy of the relative’s report or exact variant name. |
Self-pay and direct-order examples to compare
The examples below are not rankings. Prices and availability can change, and some services depend on your state, clinician order, insurance eligibility, or whether you are testing as an unaffected adult versus as part of cancer care. Before paying, verify the current checkout price, any required provider fee, sample collection method, shipping, and whether the report will be accepted by your clinician.
| Option | Published consumer price or cost policy | Mandatory fees to check | Ordering workflow | Important limitation |
|---|---|---|---|---|
| Color Hereditary Cancer Test | Color lists the Hereditary Cancer Test at $249 plus shipping and handling. The test includes BRCA1/2 as part of a hereditary cancer panel. Color cost information | Shipping and handling; confirm whether any provider or counseling services apply to your order route | Can be ordered through a provider; Color also supports consumer-facing genetic testing workflows. | Insurance billing is handled differently depending on whether the order is placed through your provider’s office. Color insurance information |
| Invitae / Labcorp genetic risk panels | Labcorp’s Invitae 2025 program lists patient-pay prices of $250 for the Invitae Cancer Genetic Risk Panel and $299 for the Comprehensive Genetic Risk Panel for eligible patient-pay use. Invitae program information | Provider visit, telehealth, or counseling charges if not included by the ordering practice | Typically ordered by a clinician through the Invitae/Labcorp workflow. | Insurance-billed testing and patient-pay testing are not always priced the same; clarify your payment path before the sample is processed. |
| Quest hereditary cancer / BRCA-related testing | Quest states that if out-of-pocket cost is estimated above $100 for BRCA-related tests, the patient or provider is notified before the test is performed; qualified patients may have out-of-pocket expense limited to $200, with $0 for some who meet income criteria. Quest financial assistance | Provider visit, collection site fees if applicable, and any insurance cost-sharing | Provider-ordered testing, often through a Quest patient service center or clinician collection process. | Self-pay prices may require Quest’s estimator and depend on test code, account, location, and coverage. |
| Myriad myRisk | Myriad states that cost depends on ordering route and insurance; if using virtual care through DNAvisit, there is a $39 test-ordering service fee, and the test cost is separate with a personalized estimate. Myriad myRisk cost information | $39 virtual-order fee when using that route; test cost, insurance cost-sharing, or cash option if offered | Through your own healthcare provider or virtual consultation. | The public page does not provide a single fixed self-pay test price; get the estimate before proceeding. |
| Ambry hereditary cancer testing | Ambry describes insurance support, a cost estimator, and self-pay options; it states that historically most patients paid $0 and those who paid averaged under $100. Ambry billing information | Provider, counseling, and collection charges; confirm exact self-pay price if insurance is not used | Clinician-ordered hereditary cancer testing. | Average historical out-of-pocket figures are not the same as a guaranteed cash-pay price. |
| 23andMe selected BRCA variant report | 23andMe Health + Ancestry pricing is sold as a consumer DNA service, not as a standalone clinical BRCA test; 23andMe states its BRCA report covers selected variants and is not comprehensive. 23andMe BRCA limitations | Kit price, subscription upgrades if chosen, and any confirmatory clinical testing later | Direct-to-consumer saliva kit. | Not a comprehensive BRCA test and should not be used alone for medical decisions. |
Bottom line: if you need a clinically actionable answer, compare clinical tests first. Consumer selected-variant reports can be interesting, but they should not be used to rule out hereditary cancer risk in someone with concerning personal or family history.
When insurance may cover BRCA testing
Insurance coverage is most likely when testing is medically indicated. The U.S. Preventive Services Task Force recommends that primary care clinicians assess women with a personal or family history of breast, ovarian, tubal, or peritoneal cancer, or ancestry associated with BRCA1/2 variants, using an appropriate risk assessment tool; those with a positive screen should receive genetic counseling and, if indicated, testing. USPSTF recommendation
Under federal preventive-care rules, many health plans must cover certain preventive services without cost sharing when provided in network. HealthCare.gov lists breast cancer genetic test counseling for higher-risk women among women’s preventive services, and government guidance links no-cost preventive coverage to USPSTF A and B recommendations. HealthCare.gov women’s preventive care
However, real-world coverage still varies. A plan may require:
- Documented personal cancer history, family history, or ancestry-related risk.
- A genetics visit or risk assessment before testing.
- Prior authorization.
- Use of an in-network lab.
- A specific test type rather than a broad panel.
- Separate handling for testing related to active cancer treatment.
If your insurer says testing is “covered,” ask what that means for your wallet. Covered can mean paid in full, or it can mean subject to deductible, copay, or coinsurance. Before your sample is run, ask the ordering office and lab for an out-of-pocket estimate and whether you can switch to self-pay if insurance would be more expensive.
Who should consider BRCA testing?
BRCA testing is most useful when the result can change medical care for you or your biological relatives. The CDC lists personal and family history patterns that may suggest increased BRCA mutation risk, such as breast cancer at a young age, ovarian cancer, male breast cancer, multiple relatives with related cancers, pancreatic or high-risk prostate cancer in the family, or Ashkenazi Jewish ancestry with related cancers. CDC BRCA risk factors
Testing is often considered for:
- Someone diagnosed with breast cancer at a young age.
- Anyone with ovarian, fallopian tube, or primary peritoneal cancer.
- People with pancreatic cancer or metastatic/high-risk prostate cancer when hereditary testing may affect treatment or relatives’ screening.
- Unaffected people with a close relative who has a known BRCA1/2 pathogenic variant.
- Families with multiple breast cancers, bilateral breast cancer, male breast cancer, or combinations of breast, ovarian, pancreatic, and prostate cancers.
The most informative person to test is usually a family member who has had a BRCA-related cancer. If that person tests positive, relatives can pursue targeted testing for the known family variant. If an unaffected person tests negative without a known familial variant, the result may be less informative because the family’s hereditary cause may be in another gene or not detectable by the chosen test.
Self-pay vs insurance: which is cheaper?
Self-pay can be cheaper when your deductible is high, your insurer requires a long authorization process, or you do not meet coverage criteria. A clear $249–$299 cash price may be preferable to an uncertain insurance claim if you are prepared to pay the full amount and the test is clinically suitable.
Insurance can be cheaper when you meet criteria and use an in-network clinician and lab. It may also be the better route if your result will guide cancer treatment, surgery decisions, screening plans, or family testing. A genetics clinic can document risk, select the correct test, and help interpret variants of uncertain significance.
Ask these questions before choosing self-pay
- Is this a comprehensive clinical BRCA1/2 test or a selected-variant consumer screen?
- Does the price include shipping both ways?
- Is a clinician order required, and is that fee included?
- Is genetic counseling included before or after testing?
- Will my doctor accept the report for medical decision-making?
- If a pathogenic variant is found, is family variant testing discounted or free for relatives?
- If the result is negative, will the lab clearly explain what was and was not ruled out?
How BRCA results are interpreted
BRCA results are usually reported using variant classifications. The American College of Medical Genetics and Genomics terminology is widely used across clinical genetics, and clinicians often group results into these practical categories:
| Result type | What it usually means | Common next step |
|---|---|---|
| Pathogenic or likely pathogenic variant | A harmful inherited variant was found that is known or strongly suspected to increase cancer risk. | Review with genetics professional; discuss screening, prevention, treatment implications if applicable, and family testing. |
| Negative when a known family variant exists | You did not inherit the specific familial variant tested. | Your cancer risk may return closer to population or family-history-based risk, depending on the family context. |
| Negative with no known family variant | No reportable harmful variant was found in the genes tested. | Do not assume hereditary risk is absent; family history may still justify enhanced screening. |
| Variant of uncertain significance (VUS) | A genetic change was found, but current evidence is not enough to label it harmful or benign. | Usually do not change major medical management based on a VUS alone; check periodically for reclassification through the ordering clinician or lab. |
A positive BRCA result can affect more than breast cancer screening. Depending on the gene, sex assigned at birth, age, family history, and medical situation, clinicians may discuss breast MRI, mammography timing, risk-reducing medication, risk-reducing surgery, ovarian cancer risk management, pancreatic screening in selected families, prostate screening, or treatment options such as PARP inhibitors for certain cancers. These decisions should be individualized with a clinician familiar with hereditary cancer guidelines.
A negative result is not always reassuring in the same way. If your mother has a documented BRCA2 pathogenic variant and you test negative for that exact variant, that is usually a strong result. If your family has several ovarian and young breast cancers but no affected relative has been tested, your negative result may be “uninformative” rather than a true rule-out.
Preparation: what to gather before ordering
Good preparation can prevent buying the wrong test. Before ordering, collect:
- Your personal cancer history: type of cancer, age at diagnosis, tumor markers if known, and treatments.
- Family history on both sides: breast, ovarian, pancreatic, prostate, colon, uterine, melanoma, gastric, endocrine, and other cancers; include ages at diagnosis.
- Known genetic results in relatives: get the actual report if possible, not just “my aunt has the gene.”
- Ancestry information: Ashkenazi Jewish ancestry and other ancestry details may affect pretest probability and test selection.
- Insurance details: deductible, network, prior authorization rules, and whether genetic counseling is covered.
- Privacy preferences: how the company stores samples, shares de-identified data, and handles research opt-in.
Genetic information can have implications for relatives. Federal GINA protections generally apply to health insurance and employment, but they do not extend to life, disability, or long-term care insurance. HHS summarizes these limits in its GINA guidance. If this issue matters to you, consider discussing timing and documentation with a genetic counselor before testing.
How to choose a BRCA testing option
Use this decision framework to narrow your options:
If a relative has a known BRCA variant
Ask for targeted family-variant testing. It is usually more precise and may be less expensive than a broad panel. Provide the lab with the relative’s report so the exact variant is tested.
If you have a strong family history but no known familial variant
A comprehensive hereditary cancer panel ordered through a clinician or reputable self-pay clinical program is usually more appropriate than a limited consumer screen. A genetics professional can decide whether BRCA-only testing or a broader panel is better.
If you currently have cancer
Work through your oncology team if possible. Germline testing may affect treatment choices, surgical decisions, and relatives’ care. Tumor testing and inherited germline testing are different; if tumor testing finds a BRCA change, NCI recommends discussing whether germline testing is needed to determine whether it was inherited.
If you are curious but have no concerning history
A consumer genetic report may be acceptable for general education, but understand its limits. A negative selected-variant report does not rule out BRCA-related hereditary cancer risk. If anxiety, family history, or medical decisions are involved, choose clinical testing and counseling.
If cost is the main barrier
Look for published cash-pay programs, financial assistance, no-cost or low-cost family testing, and labs that notify you before processing if your estimated out-of-pocket cost exceeds a threshold. Also ask hospital genetics clinics whether they can route testing through a lower-cost patient-pay lab.
Common billing mistakes to avoid
- Letting insurance billing proceed without an estimate. Ask whether you will be contacted before testing if your responsibility is above a set amount.
- Assuming “doctor ordered” means “covered.” Medical necessity, plan policy, and prior authorization still matter.
- Comparing sticker price to cash price. Insurance list charges can be much higher than patient-pay prices, but your final allowed amount may differ.
- Buying a consumer selected-variant test when you need clinical testing. This can lead to paying twice: once for the consumer kit and again for confirmatory or comprehensive testing.
- Ignoring counseling costs. Counseling may be included, optional, billed separately, or available through your health plan.
- Testing the wrong family member first. Testing an affected relative first often gives the clearest answer for the whole family.
FAQs about BRCA testing cost
How much does BRCA testing cost without insurance?
For comprehensive clinical hereditary cancer testing that includes BRCA1 and BRCA2, published self-pay prices commonly cluster around $249 to $299 before shipping, clinician, or visit fees. Some insurance-billed or hospital-billed routes can be much higher before benefits are applied.
Is BRCA-only testing cheaper than a hereditary cancer panel?
Not always. Many labs price small and broad panels similarly because the sequencing workflow is already panel-based. If a specific familial BRCA variant is known, targeted family testing may be cheaper and clearer than a broad panel.
Can I order BRCA testing myself?
Some services allow consumer-initiated testing with clinician review built into the workflow; others require your doctor, genetic counselor, nurse practitioner, or oncology team to order. State rules and lab policies can affect availability.
Is at-home saliva testing accurate?
Clinical saliva testing can be accurate when performed by a qualified clinical laboratory using validated methods. The bigger question is not saliva versus blood; it is whether the test comprehensively analyzes the right genes and variants for your situation.
What if my direct-to-consumer BRCA report is positive?
Do not make irreversible medical decisions from a consumer report alone. Contact a clinician or genetic counselor for confirmatory clinical testing and interpretation. Bring the full report, not just a screenshot.
What if my BRCA result is a VUS?
A variant of uncertain significance should usually not be treated like a positive result. Management is typically based on personal and family history unless the variant is later reclassified.
Can men use BRCA testing?
Yes. Men can inherit BRCA1 or BRCA2 variants and pass them to children. Results may affect prostate, pancreatic, male breast cancer, and family-risk decisions.
Will a negative BRCA test mean I do not need extra screening?
Not necessarily. Screening recommendations may still change based on family history, breast density, prior biopsies, other genes, or risk models. Review negative results with a clinician if your family history is concerning.
Sources and references
- National Cancer Institute: BRCA Gene Changes: Cancer Risk and Genetic Testing Fact Sheet
- National Cancer Institute: Genetic Testing Fact Sheet
- U.S. Preventive Services Task Force: BRCA-Related Cancer Recommendation
- CDC: Genetic Testing for Hereditary Breast and Ovarian Cancer
- CDC: Taking a Genetic Test on Your Own
- HealthCare.gov: Preventive Care Benefits for Women
- FDA: Direct-to-Consumer Tests
- HHS: Genetic Information Nondiscrimination Act Guidance
Use this guide to prepare for a conversation with a qualified healthcare professional, genetic counselor, or testing provider. BRCA testing can be highly useful, but the right option depends on your personal history, family history, goals, and how the result will be used.
Use the CTX Stat nationwide comparison tool to review self-pay prices across major laboratory testing providers.
